Latest News and Press Releases

BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 54,360 restricted stock units (“RSUs”) and options to...

Entrada Therapeutics reports financial results for the second quarter ended June 30, 2025, and highlights recent business updates.

Entrada Therapeutics announces the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.

Entrada Therapeutics announces inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).

Entrada Therapeutics announces that it has received authorization in the European Union to initiate its ELEVATE-45-201 clinical study.

Entrada Therapeutics, Inc. (Nasdaq: TRDA) reports financial results for the first quarter ended March 31, 2025, and highlights recent business updates.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics Receives Authorization in the UK to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44